Format

Send to

Choose Destination
Am J Hematol. 2018 Jun;93(6):729-735. doi: 10.1002/ajh.25077. Epub 2018 Mar 14.

Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers.

Author information

1
Institut d'Hématologie de Basse-Normandie, CHU, Caen, France.
2
Department of Hematology, Institut Paoli Calmettes, Marseille.
3
Department of Clinical Hematology, University Hospital Montpellier, Montpellier, France.
4
Hematology Department, Centre Antoine Lacassagne, Nice, France.
5
Hematology, Toulouse University Hospital, Toulouse, France.
6
Clinical Research Department, Amiens University hospital, Amiens, EA4666, France.
7
Haematology, University Hospital, Strasbourg, France.
8
Hematology, University hospital, Rennes, France.
9
Department of Hematology, Nantes University Hospital, Nantes, France.
10
Department of Hematology, Curie Institute, Hôpital René Huguenin, Saint-Cloud, France.
11
Service d'hématologie clinique adulte et de thérapie cellulaire, CHU ESTAING, EA 7453 CHELTER, Université Clermont Auvergne CIC-501, Clermont-Ferrand, France.
12
Oncopole Hopital Sud, Amiens, FRA.
13
Makassed General Hospital, Beirut, LBN.
14
Institut d'Hématologie de Basse-Normandie, Centre François Baclesse, Caen, France.
15
Hematology and Cell Therapy, Etablissement Hospitalier Universitaire (EHU) 1st November, Oran, Algeria.
16
Hematology, University Hospital, Dijon, France.
17
Hematology, CHU Grenoble, Grenoble, France.
18
Oncologie hématologique et thérapie cellulaire, CHU Poitiers, Poitiers, France.
19
Hematology, Hôpital HURIEZ UAM allogreffe de CSH, CHRU, Lille, France.
20
Haematology, CHU de Bordeaux, Bordeaux, France.
21
Department of Hematology, Centre Hospitalier Universitaire, Reims Cedex, FRA.
22
Microenvironnement Cellulaire et Pathologies, Normandie Univ, Unicaen, MILPAT, Caen, 14000, France.

Abstract

Carmustine shortage has led to an increase use of alternative conditioning regimens prior to autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine-based (BeEAM). The aim of this study was to evaluate the safety of the BeEAM regimen in a large cohort of patients. A total of 474 patients with a median age of 56 years were analyzed. The majority of patients had diffuse large B-cell lymphoma (43.5%). Bendamustine was administered at a median dose of 197 mg/m2 /day (50-250) on days-7 and -6. The observed grade 1-4 toxicities included mucositis (83.5%), gastroenteritis (53%), skin toxicity (34%), colitis (29%), liver toxicity (19%), pneumonitis (5%), and cardiac rhythm disorders (4%). Nonrelapse mortality (NRM) was reported in 3.3% of patients. Acute renal failure (ARF) was reported in 132 cases (27.9%) (G ≥2; 12.3%). Organ toxicities and death were more frequent in patients with post conditioning renal failure. In a multivariate analysis, pretransplant chronic renal failure, bendamustine dose >160 mg/m2 and age were independent prognostic factors for ARF. Pretransplant chronic renal failure, hyperhydration volume, duration of hyperhydration, and etoposide dose were predictive factors of NRM. A simple, four-point scoring system can stratify patients by levels of risk for ARF and may allow for a reduction in the bendamustine dose to avoid toxicity. Drugs shortage may have dangerous consequences. Prospective, comparative studies are needed to confirm the toxicity/efficacy extents from this conditioning regimen compared to other types of high dose therapy.

PMID:
29473209
DOI:
10.1002/ajh.25077
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center